Showing results (231-240 of 253) with videos related to

Sort By:
Pageof 26
Prostate Cancer and Prostatic Diseases|June 3, 2005
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programmeM Wirth, C Tyrrell, K Delaere, et al.
Hepatobiliary Surgery and Nutrition|June 9, 2020
Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancerScott Kizy, Ariella M Altman, Keith M Wirth, et al.
Annals of Surgery|April 1, 2020
Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis: A Retrospective Cohort AnalysisKeith M Wirth, Adam C Sheka, Scott Kizy, et al.
Urology|August 8, 2001
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progressionM Wirth, C Tyrrell, M Wallace, et al.
Der Urologe. Ausg. A|May 8, 1999
[Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle]H J Luboldt, J E Altwein, K H Bichler, et al.
Molecular Cancer Research : MCR|April 28, 2023
Desmoglein 2 Functions as a Receptor for Fatty Acid Binding Protein 4 in Breast Cancer Epithelial CellsDongmei Chen, Keith M Wirth, Scott Kizy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancerS D Baker, M Wirth, P Statkevich, et al.
Aktuelle Urologie|May 31, 2006
[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma]K Miller, K Becker, F Finke, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factorH Stöger, H Samonigg, M Krainer, et al.
Nature Nanotechnology|July 17, 2020
COVID-19 vaccine development and a potential nanomaterial path forwardMatthew D Shin, Sourabh Shukla, Young Hun Chung, et al.
Pageof 26